This week Hill-Rom (NYSE: HRC) is featuring the Progressa® bed system, the next generation of intensive care unit (ICU) bed systems, at the American Organization of Nurse Executives (AONE) annual meeting in Orlando, Fla. The Progressa bed system is a therapeutic system designed to treat and prevent complications of immobility. It features a state-of-the-art design that supports treatment goals and was engineered to help address patient migration via its StayInPlace™ technology.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/66137-hill-rom-new-progressa-bed-system
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7224051-issels-integrative-immunotherapy-lung-cancer-advanced-treatment
Entering its 10th year of providing gout education, the Gout & Uric Acid Education Society (GUAES) is amplifying its efforts on May 22 – National Gout Awareness Day – and encouraging gout sufferers to seek immediate and ongoing treatment. Information and resources are available to both the general public and medical professionals through the organization’s new website, found at GoutEducation.org.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7134051-gout-and-uric-acid-education-society-national-gout-awareness-day
Maini & Magneto Dayo's single Blue Song is released worldwide on June 9th 2014. Magneto Dayo is an American rapper from Brooklyn. Maini Sorri is a pop/electronica artist from Sweden with hits like Let Me Do Your Time. The Blue Song video is directed by Johan Zetterlund, Sweden. Maini Sorri has written the music, lyrics are by Gary Cornman USA and Dashawn Williams New York, the remix is by Carsten Lehmann from Germany. The label behind the release is Reya music, Sweden.
BLUE SONG
Music by Maini Sorri
Lyrics by Gary Cornman & Dashawn Williams
1. The silent treatment
seems to be frequent.
Sit by the window
I'm feeling so low.
2. Mind boggling insane
can almost touch pain
rain's running down panes
within window frames.
Chore: Drops of rain paint the picture
and my tears add the texture.
Wracked my brain wondering why
there's no answer though I try.
(TALKING) Magneto Dayo, I see you Maini Dayo Dayo
She's wondering why its different/ and why I'm keeping a distance, and giving the silent treatment, because she's not willing to listen/ we went from building a friendship, Now we're feeling resentment/ but neither one of us really has the guts to end it/ and arguing is starting to become a part of us/ and the bruises we took in the past is why our guards is up/ I apologize for acting disloyal/ my morals were destroyed by the one I had before you/ its sad but its all true/ love is a gamble and I loss too/ so this go round i really can't afford to/ seen people go from having wedding/ no happily ever after instead its/ collapsing ahead of them as they battle depression
2. Mind boggling insane
can almost touch pain
rain's running down panes
within window frames.
Chore: Drops of rain paint the picture
and my tears add the texture.
Wracked my brain wondering why
there's no answer though I try.
Chore: Drops of rain paint the picture
and my tears add the texture.
Wracked my brain wondering why
there's no answer though I try.
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
The Celiac Disease Center at Columbia University, the premier center for celiac disease research and treatment, unveiled the I Didn’t Know video campaign, offering an inside look at the serious impact of celiac disease on patients at the 13th Anniversary gala on November 13th in New York City. The series chronicles the lives of several patients experiencing a wide range of debilitating symptoms associated with undiagnosed celiac disease, including an inability to walk, developmental delays, multiple miscarriages and infertility.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7322351-celiac-disease-center-at-columbia-university-public-service-announcements-and-gala/
Eight out of 10 people will be affected by back pain at some point during their lives, making it the No. 1 cause of disability worldwide and resulting in as much as $200 billion in lost wages and productivity. Many sufferers struggle for years to find relief, but treatment options often only provide short-term relief or, in the case of pain medication, carry serious side effects, including drowsiness, liver damage and potential for addiction. Now, thanks to Hocoma, a leader in the development of robotic and sensor-based medical devices for functional movement therapy, consumers have a new way to improve and sustain low back health in the comfort of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7370551-hocoma-innovative-medical-device-therapeutic-gaming-technology-valedo-low-back-health/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
Today, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced the launch of ‘Cuida tu Don,’ a national public awareness initiative featuring legendary entertainer Mario Kreutzberger, better known as ‘Don Francisco.’ Kreutzberger, who has type 2 diabetes, will serve as an ambassador for the initiative and encourage Hispanics with type 2 diabetes to live a lifestyle conducive to staying healthy. ‘Cuida tu Don,’ translated as ‘Take Care of Your Gift,’ is designed to engage, educate and inspire Hispanics with type 2 diabetes and their families. The initiative provides resources and information in three key aspects of diabetes – nutrition, fitness and treatment options – to the estimated 3.2 million Hispanics in the United States with the disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7401451-boehringer-ingelheim-diabetes/
New data from a school asthma management program, “Building Bridges for Asthma Care,” presented today at the American Thoracic Society 2015 International Conference, show a significant decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Absences dropped 11.75 percent among children enrolled in Building Bridges, compared to an increase of 8.48 percent in children with asthma not in the program.
“Building Bridges for Asthma Care” is a school-based program designed to empower nurses in participating elementary schools to ensure that asthmatic children are identified and provided care according to the National Institute of Health’s clinical treatment guidelines. The objectives of the program are addressing the risk of health disparities and asthma-related absenteeism, as well as its related impact on academic achievement for inner city students.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7506851-gsk-building-bridges-for-asthma-care/
